High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: A critical review

Current Stem Cell Research and Therapy

Volumn 2, Issue 1, 2007, Pages 65-82

  Luigi Banna, Giuseppe ^a   Simonelli, Matteo ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Autologous hemopoietic stem cell transplantation; Breast cancer; Dose intensity; Dose response; High dose chemotherapy; Solid tumor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EDETIC ACID; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PLATINUM DERIVATIVE; THIOTEPA; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPERIMENTAL DESIGN; GERM CELL TUMOR; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; IN VITRO STUDY; INFECTION; LEUKEMIA; LUNG SMALL CELL CANCER; LUNG TOXICITY; MEDICAL INFORMATION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; RHABDOMYOSARCOMA; SEIZURE; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 34248200099     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488807779316964     Document Type: Review

References (173)

1. Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-94.
2. Frei E 3rd, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417-23.
3. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988; 6: 1501-15.
4. De Vita VT. In: De Vita VT, Hellman S, Rosenberg SA Ed, Cancer Principles and Practice of Oncology. Philadelphia, JB Lippincott 1989; 276-300.
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
6. Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14 (suppl 4): 29-33.
7. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971; 28: 1479-1499.
8. Skipper HE. Analysis of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities. South Res Inst Booklet 1986; 420: 87-92.
9. Norton L. Adjuvant breast cancer therapy: Current status and future strategies - growth kinetics and the improved drug therapy of breast cancer. Semin Oncol 1999; 26 (suppl 3): 1-4.
10. Hudis C, Norton L. Adjuvant drug therapy for operable breast cancer. Semin Oncol 1996; 23: 475-493.
11. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, systemic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
12. Norton L. Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy. Oncologist 2001; 6 (suppl 3): 30-35.
13. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5: 935-41.
14. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomised comparison. J Clin Oncol 1995; 13: 1328-35.
15. Schabel Jr FM, Trader MW, Laster Jr WR, Wheeler GP, Witt MH. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 1978; 23: 200-15.
16. Rodenhuis S, Richel DJ, Van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support inoperable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515-21.
17. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 2002; 13: 689-98.
18. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-91.
19. Bergh J. Long-term follow-up of the randomized Scandinavian Breast Group (SBG) study 9401 comparing standard FEC followed by marrow supported high dose therapy versus tailored and dose-escalated FEC therapy. Proc Am Soc Clin Oncol 2003. abstract 94.
20. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225-33.
21. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
22. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high risk breast cancer. N Engl J Med 2003; 349: 17-26.
23. Zander AR, Kroger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004; 22: 2273-83.
24. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005; 23: 2191-200.
25. Leonard RC, Lind M, Twelves C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograftsupported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 2004; 96: 1076-83.
26. Nitz UA, Mohrmann SA, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005; 366: 1935-44.
27. Roche HH, Pouillart P, Meyer N, et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N > 7) breast cancer patients: The Pegase 01 Trial. Proc Am Soc Clin Oncol 2001. abstract 102.
28. Gianni A, Bonadonna G. Five-year results of the randomised clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN). Proc Am Soc Clin Oncol 2001. abstract 80.
29. Tokuda Y, Tajima T, Narabayashi M, et al. Randomized phase III study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology Group (JCOG9208). Proc Am Soc Clin Oncol 2001. abstract 148.
30. Basser R, O'Neill A, Martinelli G, et al. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15-95. Proc Am Soc Clin Oncol 2003. abstract 20
31. Bliss JM, Vigushin D, Kanfer E, et al. Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes (ISRCTN: 52623943). Proc Am Soc Clin Oncol 2003. abstract 58.
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
33. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
34. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069-76.
35. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem-cell transplantation (SCT) for metastatic breast cancer: 5-year update of the Philadelphia trial (PBT-1). Proc Am Soc Clin Oncol 2002. abstract 169.
36. Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 2005; 41: 71-80.
37. Peters WP, Jones RB, Vredenburgh JJ, et al. A large, prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction chemotherapy (AFM). Proc Am Soc Clin Oncol 1996. abstract 149.
38. Biron P, Durand M, Roche H, et al. High-dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole. Proc Am Soc Clin Oncol 2002. abstract 167.
39. Crown JP, Perey L, Lind M, et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol 2003. abstract 88.
40. Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743-50.
41. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707-18.
42. Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001; 19: 628-33.
43. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003; 349: 80-2.
44. Elfenbein GJ. Clinical trials and survival curves: the shape of things to come. Acta Haematol 2001; 105: 188-94.
45. The International Germ-Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
46. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
47. Rosti G, Ferrante P. In: C.E.L.I. Ed, EBMT Solid Tumors Working Party and Registry 2000 Report. Faenza, C.E.L.I. 2001; 49-56.
48. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346-51.
49. Broun ER, Nichols CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 1997; 79: 1605-10.
50. De Giorgi U, Rosti G, Papiani G, Marangolo M. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor. Haematologica 2002; 87: 95-104.
51. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21: 4100-4104.
52. Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 2002; 13: 599-605.
53. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152-9.
54. Rodenhuis S, de Wit R, de Mulder PH, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999; 10: 1467-73.
55. Ayash LJ, Clarke M, Silver SM, et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant 2001; 27: 939-47.
56. Margolin BK, Doroshow JH, Ahn C, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996; 14: 2631-7.
57. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-80.
58. Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19: 81-8.
59. Shamash J, O'Doherty CA, Oliver RT, et al. Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours? Acta Oncol 2000; 39: 857-63.
60. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-2552.
61. Bosl GJ, Geller NL, Bajorin D. Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1988; 15: 339-44.
62. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456.
63. De Giorgi U, Rosti G, Papiani G et al. Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience. Bone Marrow Transplant 2004; 33: 639-643.
64. Rosti G, De Giorgi U, Wandt H et al. First line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 2004; 34: 1033-1037.
65. Decatris MP, Wilkinson PM, Welch RS et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 2000; 11: 427-434.
66. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomised trial. Eur Urol 1993; 23: 213-7.
67. Ozols RF, Schwartz PE, Eifel PJ. In: DeVita Jr. VT, Hellman S, Rosenberg SA Ed, Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. Cancer: Principles and Practice of Oncology, Sixth Edition. Philadelphia, Lippincott Williams & Wilkins 2001; 1597-1632.
68. Rubin SC, Hoskins WJ, Hakes TB et al. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988; 159: 1094-8.
69. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
70. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (suppl 5): 20-8.
71. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-67.
72. Shpall EJ, Clark-Pearson D, Soper JT, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386-91.
73. Mulder PO, Willemse PH, Aalders JG, et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 1989; 25: 645-9.
74. Ellis ED, Williams SF, Moormeier JA, Kaminer LS, Bitran JD. A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplant 1990; 6: 439-42.
75. Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1: 359-67.
76. Corringham R, Gilmore M, Prentice HG, Boesen E. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer 1983; 52: 1783-7.
77. Shea TC, Flaherty M, Antman K, et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-61.
78. Viens P, Maraninchi D, Legros M, et al. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227-33.
79. Holmberg LA, Demirer T, Rowley S, et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651-9.
80. Grenman SE, Rantanen VT, Salmi TA. High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer. Ann Med 1996; 28: 151-8.
81. de Vries EG, Hamilton TC, Lind M, et al. Advanced ovarian cancer. Drug resistance, supportive care and dose intensity. Ann Oncol 1993; 4 (suppl 4): 57-62.
82. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-17.
83. Viens P, Gravis G, Blaise D, et al. High-dose chemotherapy (HDC) with bone marrow rescue for patients with FIGO stage III-IV common epithelial ovarian carcinoma responding to first line treatment. Proc Am Soc Clin Oncol 1995; 14: 285.
84. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-8.
85. Stiff PJ, Veum-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000; 133: 504-15.
86. Ledermann JA, Herd R, Maraninchi D, et al. High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2001; 12: 693-9.
87. Cure H, Battista C, Guastalla JP, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC):5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2004. abstract 5006.
88. Bengala C, Guarneri V, Ledermann J, et al. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2005; 36: 25-31.
89. Ledermann JA, Frickhofen N, Wandt H, et al. A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose Chemotherapy (SDC) for first-line treatment of ovarian cancer. Proc Am Soc Clin Oncol 2005. abstract 5006.
90. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a metaanalysis. Lancet 1993; 342: 19-21.
91. Fischer JR, Manegold C, Bülzebrück H, et al. Induction chemotherapy with and without human granulocyte colony-stimulation factor in locally advanced IIIA/IIIB non-small cell lung cancer. Semin Oncol 1994; 3 (suppl 4): 20-7.
92. Mori Y, Saitoh Y, Tominage K, et al. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer. Eur J Cancer 1993; 5: 677-85.
93. Palackdharry CS, Krigel RL. Dose-intensive ifosfamide/carboplatin/ etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer. Semin Oncol 1994; 21 (suppl 4): 6-11.
94. Fetscher S. The role of high-dose chemotherapy in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 41: 151-6.
95. Fetscher S, Brugger W, Engelhardt R, et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. Ann Oncol 1999; 10: 605-7.
96. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-271.
97. Osterlind K, Hansen H, Hansen M, et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986; 4: 1307-1313.
98. Thomas CR, Giroux DJ, Janaki LM, et al. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer 2001; 33: 213-219.
99. Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twicedaily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14: 806-813.
100. Rizzo JD, Elias Ad, Stiff PJ, et al. Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant 2002; 8: 273-80.
101. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomised controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-9.
102. Steward W, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose-intensification of VICE chemotherapy in small-cell lung cancer (SCLC): a prospective randomised study of 300 patients. J Clin Oncol 1998; 16: 642-50.
103. Thatcher N, Girling D, Hopwood P, Sambrook R, Qian W, Stephens R. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony stimulating factor support: results of a British MRC multi-centre randomised trial. J Clin Oncol 2000; 18: 395-404.
104. James L, Gower N, Rudd R, Spiro S, Harper P, Trask C, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1996; 73: 1563-8.
105. Pujol JL, Douillard JY, Riviere A, et al. Dose intensity with four drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony stimulating factor in extensive stage small-cetl lung cancer: a multi-centre randomised phase III trial. J Clin Oncol 1997; 15: 2082-9.
106. Ardizzoni A, Tjan-Heijnen V, Postmus P, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organisation for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002; 20: 3947-55.
107. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848-1852.
108. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864-73.
109. Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005; 97: 666-74.
110. Turrisi AT 3rd, Glover DJ. Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 1990; 19: 1473-1479.
111. Elias A, Ibrahim J, Skarin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999;17:1175-1184.
112. Tomeczko J, Pacuszko T, Napora P, et al. Treatment intensification which includes high dose induction improves survival of lung carcinoma patients treated by high dose chemotherapy with hematopoietic progenitor cell rescue but does not prevent high rate of relapses. Bone Marrow Transplant 1996; 18 (suppl 1): 44-7.
113. Brugger W, Fetscher S, Hasse J, et al. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 1998; 5 (suppl 2): 42-8.
114. Jennis A, Levitan N, Pecora AL, et al. Sequential high dose chemotherapy with filgrastim/peripheral stem cell support in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1996. abstract 349.
115. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest 1999; 116 (suppl): 531-8.
116. Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E 3rd. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant 2002; 8: 326-33.
117. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221-7.
118. Dumontet C, Biron P, Bouffet E, et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transpl 1992; 10: 405-8.
119. Elias AD, Ayash LJ, Eder JP, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991; 9: 320-7.
120. Mesia R, Sola C, Lopez PA, et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994; 194: 960-5.
121. Blay JY, Bouhour D, Ray-Coquard I, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643-50.
122. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998; 16: 1438-1443.
123. Ray-Coquard I, Biron P, Blay JY. High-dose chemotherapy in soft tissue sarcomas of adults. Bull Cancer 2001; 88: 858-862.
124. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676-84.
125. Worden FP, Taylor JM, Biermann JS, et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005; 23: 105-12.
126. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002; 20: 2150-6.
127. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000; 11: 1451-62.
128. Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/ melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transpl 1997; 20: 843-6.
129. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482-8.
130. Hartmann O, Oberlin O, Beaujean F, et al. Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing's sarcoma in children. Bull Cancer 1990; 77: 181-7.
131. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911-8.
132. Nieboer P, de Vries EG, Mulder NH, van der Graaf WT. Relevance of high-dose chemotherapy in solid tumours. Cancer Treat Rev 2005; 31: 210-25.
133. Bertuzzi A, Castagna L, Nozza A, et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20: 2181-8.
134. Dunkel IJ, Finlay JL. High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit Rev Oncol Hematol 2002; 41: 197-204.
135. Linassier C, Ben Hassel M, Figarella-Branger D, et al. Phase III study comparing high-dose BCNU with autologous blood stem cell support versus standard dose BCNU, in combination with radiotherapy after gross total resection in patients with supratentorial glioblastoma. Proc Am Soc Clin Oncol 2003. abstract 399.
136. Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 1996; 27: 87-98.
137. Mahoney DH Jr., Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/ progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 1996; 14: 382-8.
138. Graham ML, Herndon JE Jr., Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15: 1814-23.
139. Dunkel IJ, Boyett JM, Yates A, et al. High dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998; 16: 222-8.
140. Grill I, Kalifa C, Doz F, et al. A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma: a phase II study. Pediatr Neurosurg 1996; 25: 7-12.
141. Mason WP, Goldman S, Yates AJ, Boyett J, Li H, Finlay JL. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma - a report of the Children's Cancer Group. J Neurooncol 1998; 37: 135-43.
142. Kedar A, Maria BL, Graham-Pole J, et al. High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med Pediatr Oncol 1994; 23: 428-36.
143. Dunkel IJ, Garvin JH, Goldman S, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. J Neurooncol 1998; 37: 67-73.
144. Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 2000; 88: 685-92.
145. Saarinen UM, Pihko H, Makipernaa A. High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report. J Neurooncol 1990; 9: 57-61.
146. Cairncross G, Swinnen L, Stiff P, et al. High-dose thiotepa with hematopoietic reconstitution (deferring radiation) for newly diagnosed
147. Lazarus HM, Reed MD, Spitzer TR, et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689-95.
148. Rosti G, Ferrante P, Ledermarm J, et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 2002; 41: 129-40.
149. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-38.
150. Wilkin A, Freinberg J. Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation. Oncology (Williston Park) 2000; 14: 1701-8.
151. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-87.
152. Fetscher S, Finke J, Engelhardt R, et al. Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Ann Hematol 1997; 74: 73-7.
153. Kroger N, Zander AR, Martinelli G, et al. Low incidence of secondary myelodysplasia and acute myeloid leukaemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2003; 14: 554-8.
154. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005; 97: 1724-33.
155. Fossa SD, Paluchowska B, Horwich A, et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell turnouts (EORTC trial 30948). Br J Cancer 2005; 93: 1209-14.
156. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-8.
157. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-70.
158. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6.
159. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
160. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005; 5: 899-904.
161. Sanai N, Halvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-22.
162. Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell 1991; 64: 337-50.
163. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994; 70: 6-22.
164. Dahmane N, Sanchez P, Gitton Y, et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001; 128: 5201-12.
165. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
166. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
167. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005; 45: 872-7.
168. Banna GL, Aversa S, Chiarion-Sileni V, Favaretto A, Ghiotto C, Monfardini S. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 2004; 51: 171-89.
169. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-20.
170. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
171. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
172. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
173. Elias AD, Ibrahim J, Richardson P, et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transpl 2002; 8: 198-205.